PDS Biotechnology Corporation (PDSB)
| Market Cap | 47.14M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -37.61M |
| Shares Out | 37.41M |
| EPS (ttm) | -1.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 220,301 |
| Open | 1.180 |
| Previous Close | 1.250 |
| Day's Range | 1.190 - 1.290 |
| 52-Week Range | 1.130 - 4.420 |
| Beta | 1.67 |
| Analysts | Strong Buy |
| Price Target | 10.00 (+693.65%) |
| Earnings Date | Mar 27, 2025 |
About PDSB
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company’s lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunolog... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for PDSB stock is "Strong Buy." The 12-month stock price forecast is $10.0, which is an increase of 693.65% from the latest price.
News
PDS Biotechnology Corporation (PDSB) Q4 2024 Earnings Call Transcript
PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Tom Johnson - LifeSci Advisors Frank Bedu-Addo - CEO Kirk Shepard - Chief M...
PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update
Initiated VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune ® HPV in HPV16-Positive Head and Neck Cancer
PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference
PRINCETON, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the im...
PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results
PRINCETON, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the im...
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer
Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer Institute Second Versamune ® platform candidate targets MUC1-positive solid tumors U.S. Patent #12...
PDS Biotech Leadership to Participate in March Conferences
PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the im...
PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer
First-ever HPV16-positive head and neck cancer Phase 3 clinical trial First-ever HPV16-positive head and neck cancer Phase 3 clinical trial
PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
PRINCETON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the imm...
PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology
Median Overall Survival (mOS) of 42.4 months in immune checkpoint inhibitor naïve patients; Historical published result is 7-12 months Continued survival in the cohort of HPV16-positive immune checkpo...
PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research
Data confirms Versamune ® HPV has potential as a broadly effective treatment of HPV16-associated cancers – Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025
PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025
PRINCETON, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the imm...
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the imm...
PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET
Discussion topics to include pathology and prevalence of HPV16-positive head and neck cancer, VERSATILE-003 Phase 3 clinical trial design and initiation Discussion topics to include pathology and prev...
PDS Biotechnology Corporation (PDSB) Q3 2024 Earnings Call Transcript
PDS Biotechnology Corporation (NASDAQ:PDSB) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Tom Johnson - LifeSci Advisors Frank Bedu-Addo - Chief Executive Officer...
PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time
PRINCETON, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the imm...
PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation
100% 36-month overall survival (OS) and progression-free survival (PFS) rates in patients fully treated with Versamune ® HPV combined with chemoradiation (N=8) 88% (15/17) of patients had a complete ...
PDS Biotechnology: Continuing The Holding Pattern
PDS Biotechnology is focusing on an HPV-directed immunotherapy as its main near-term hope, with new data presented at the ESMO Congress. Strengths include promising clinical data and a focused pipelin...
PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024
PRINCETON, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the im...
PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference
PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the im...
PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024
PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the imm...
PDS Biotechnology Corporation (PDSB) Clinical Program Update Conference Call (Transcript)
PDS Biotechnology Corporation (NASDAQ:PDSB) Clinical Program Update Conference Call August 1, 2024 8:00 AM ET Company Participants Mike Moyer - LifeSci Advisors Frank Bedu-Addo - Chief Executive Offi...
PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer
Company to initiate Phase 3 VERSATILE-003 trial in Q4 2024 Conference Call Today at 8:00 a.m. Eastern Time PRINCETON, N.J.
PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time
PRINCETON, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the imm...
PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results
Provided Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
30 month median overall survival (OS); median OS independent of patient CPS score ORR 34% (CPS≥1); 48% (CPS≥20) Phase 3 registrational trial planned to initiate in 2024 PRINCETON, N.J., May 09, 2024 (...